<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1428">
  <stage>Registered</stage>
  <submitdate>28/06/2006</submitdate>
  <approvaldate>7/07/2006</approvaldate>
  <actrnumber>ACTRN12606000288527</actrnumber>
  <trial_identification>
    <studytitle>The effect on sleep quality of two levels of heated humidification (during nasal Continuous Positive Airway Pressure therapy) on sleep quality. TS-NILIa</studytitle>
    <scientifictitle>The effect of two levels of heated humidification (during nasal Continuous Positive Airway Pressure therapy for Patients with Obstructive Sleep Apnea) on sleep quality. TS-NILIa</scientifictitle>
    <utrn />
    <trialacronym>TS-NILIa</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>STUDY ARMS: 

CPAP + (optimal level of humidity) 

STAGE 1:
Participants will be randomised to 2 nights of full sleep study. (one night on each of the study arms)

Outcome measures:
Sleep quality (measured once after each nightime study) 


STAGE 2: 
After completion of  stage 1 of the study particpants will be re-randomised to one of the two study arrms for three weeks at home on this arm. After completion of this 3 weeks  particpants will be swapped to the alternate arm.   


Outcome measures:
Compliance (recorded at the end of each 3-week arm)
Subjective symptom score;  relating to comfort (recorded at the end of each 3-week arm)</interventions>
    <comparator>CPAP + (conventional heated humidification)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sleep Quality</outcome>
      <timepoint>Measured during each overnight study (i.e. twice per study subject)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective symptom score relating to comfort </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compliance</outcome>
      <timepoint> Recorded at the end of each three week arm.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Newly diagnosed obstructive sleep apnea &gt; 10 AHI.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Therapy  intolerance determined in the PSG-CPAP titration studyVentilatory insufficiencyMalignant herat rythmn Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed Envelopes</concealment>
    <sequence>Computer generated randomization sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/04/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>self funded by hospital -Klinik Ambrock, Klinik fur Pneumologie, Universitat Witten-Herdecke, Hagen.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Germany</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>hospital- Klinik Ambrock</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Klinik fur Pneumologie</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Universitat Witten-Herdecke, Hagen</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Fisher and Paykel Healthcare</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to ascertain if delivering higher levels of humidity to patients undergoing CPAP treatment for Obstructive Sleep Apnea will result in greater comfort; better sleep quality and increased compliance with treatment. Our hypothesis is that supports this theory. 

There are two STUDY ARMS: 
CPAP + (conventional heated humidification)
CPAP + (optimal level of humidity) 

STAGE 1:
Participants will be randomised to 2 nights of full sleep study. (one night on each of the study arms)

Outcome measures:
Sleep quality (measured once after each nightime study) 


STAGE 2: 
After completion of  stage 1 of the study particpants will be re-randomised to one of the two study arrms for three weeks at home on this arm. After completion of this 3 weeks  particpants will be swapped to the alternate arm.   


Outcome measures:
Compliance (recorded at the end of each 3-week arm)
Subjective symptom score;  relating to comfort (recorded at the end of each 3-week arm)</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Klinik Ambrock, Klinik fur Pneumologie, Universitat Witten-Herdecke- the ethical commission of the university Witten/Herdecke</ethicname>
      <ethicaddress>Alfred-Herrhausen-Str. 50 D58448 Witten</ethicaddress>
      <ethicapprovaldate>26/04/2006</ethicapprovaldate>
      <hrec>26/2006</hrec>
      <ethicsubmitdate />
      <ethiccountry>Germany</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Georgina Cuttance</name>
      <address>15 Maurice Paykel Place 
East Tamaki 
Auckland</address>
      <phone>+64 9 5740123 ext. 8822</phone>
      <fax />
      <email>Georgina.cuttance@fphcare.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Georgina Cuttance</name>
      <address>15 Maurice Paykel Place 
East Tamaki 
Auckland</address>
      <phone>+64 9 5740123 ext. 8822</phone>
      <fax />
      <email>Georgina.cuttance@fphcare.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>